Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT07342634
Recruiting Not applicable

Effect of Blood Flow Restriction on Recovery After Maximal Resistance Exercise

NCT07342634 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2026-02-01
Last updated
2026-09-16

Condition(s) studied

RecoveryRecovery Time

Investigational drug(s) / intervention(s)

BFR-80%BFR-60%BFR-10mmHg

BFR-80%: Will perform the intervention with BFR using 80% of the total occlusion pressure (TOP) continuously for 20 minutes.

BFR-60%: Will perform the intervention with BFR using 60% of the total occlusion pressure (TOP) continuously for 20 minutes.

BFR-10mmHg: Will perform the intervention with BFR using 10 mmHg of occlusion pressure continuously for 20 minutes.

Study summary

Resistance training has been widely performed due to its health benefits. However, performing this training at high intensity causes significant muscle stress, leading to fatigue and compromising performance. It is essential to implement effective recovery strategies to optimize physiological adaptations. Among the accessible techniques, blood flow restriction (BFR) has shown promise for its potential to accelerate muscle recovery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Individuals exhibiting one or more of the following characteristics will not be included: * (1) diabetes and hypertension; * (2) inflammatory rheumatological, psychiatric, cardiovascular and/or respiratory disease; * (3) pre-existing injury restricting their ability to perform vigorous physical activities; * (4) having one or more predisposing risk factors for thromboembolism. Exclusion Criteria: * Participants will be excluded from the study if they: * (1) have a health problem that does not allow them to continue; * (2) wish to leave the study; * (3) use medications, electrotherapy, or other therapeutic methods during the study period that could interfere with any results; * (4) not sign the consent form.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Franciele Marques Vanderlei Presidente Prudente São Paulo Recruiting

More Paulista University trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07342634 on ClinicalTrials.gov ↗ ← All trials in Brazil